激光脱毛(LHR)已被确立为用于消除多余毛发的安全且有效的方法。本研究旨在调查LHR并发症的发生频率并评估其影响因素。在一年中,评估了16,900名接受LHR治疗的患者的并发症。对于每种情况,选择了两个外部对照(根据年龄匹配,性别,Fitzpatrick皮肤型(FST)III-IV,和治疗的解剖区域)。为了评估解剖区域对并发症发生的影响,如果在同一疗程期间接受其他区域治疗,则每位患者均用作内部对照.采用GEE分析进行统计学分析。LHR并发症的发生率为0.69%。最常见的并发症是瘀斑,紫癜,瘀斑(31.66%),其次是色素沉着变化(20.0%)。LHR并发症最常见于下肢(32.0%),面部和颈部(23.3%),以及生殖器和大腿(22.3%),分别。可能的危险因素为年龄较小(OR=0.74,P值≤0.001),在头部和颈部操作LHR(OR=5.8,P值=0.022),利用翠绿宝石激光(OR=2.32,P值=0.011),和宝石激光中的通量(OR=3.47,P值=0.003)。总的来说,这项研究的结果表明,LHR通常是去除多余毛发的安全方法。然而,因素,如年龄,面部区域的治疗,在FSTIII-IV患者中,尤其是在通量水平较高的情况下,使用翠绿宝石激光被确定为潜在的危险因素。
Laser hair removal (LHR) has been established as a safe and efficient method for eliminating unwanted hair. This study aimed to investigate the frequency of LHR complications and assess the contributing factors. During one year, 16,900 patients undergoing LHR therapy were evaluated for complications. For each case, two external controls were selected (matched based on age, sex, Fitzpatrick skin type (FST) III-IV, and the treated anatomical region). To assess the impact of anatomical region on complication occurrence, each patient was used as their internal control if another area was treated during the same session. GEE analysis was used for statistical analysis.The incidence of LHR complications was calculated to be 0.69%. The most common complications were petechia,
purpura, and ecchymosis (31.66%) followed by pigmentation changes (20.0%). LHR complications were most commonly observed in the lower limbs (32.0%), face and neck (23.3%), and genitalia and thighs (22.3%), respectively. Possible risk factors were younger age (OR = 0.74, P-value ≤ 0.001), operating LHR in the head and neck (OR = 5.8, P-value = 0.022), utilization of the alexandrite laser (OR = 2.32, P-value = 0.011), and fluence in the Alexandrite laser (OR = 3.47, P-value = 0.003).Overall, the results of this study indicate that LHR is generally a safe method for removing unwanted hair. However, factors such as younger age, treatment of the facial area, and use of the alexandrite laser especially with higher fluence levels in patients with FST III-IV were identified as potential risk factors.